

28th October 2010, Mumbai, India

GlaxoSmithKline Pharmaceuticals Net Sales up 14%, PBT before Exceptional Items grows by 14%

GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2010. The Company has posted a Net Sales growth of 14% compared to the previous quarter, while Profit Before Tax and before Exceptional Items has grown by 14%, on a comparable basis. The core pharmaceutical business grew at 15%

Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, “The pharmaceutical business registered all round growth with the mass markets, mass specialities and specialities businesses all showing strong market competitive growth. The Company gained market share during the quarter. Vaccines registered a handsome growth as well. New products launched in the last two years continue to accelerate growth”

During the quarter, approval has been received for Revolade, a drug for low platelet counts and Votrient, for metastatic renal cell carcinoma.

About GlaxoSmithKline:

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.

For enquiries, please contact:

Sunder Rajan,
General Manager, Corporate Communications

+91 22 24959203
sunder.r.rajan@gsk.com